MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Olverembatinib dimesylate

CAS No. : 1421783-64-3

MCE 站：Olverembatinib dimesylate

产品活性：Olverembatinib (GZD824) dimesylate 是一种高效的，具有口服活性的 pan-Bcr-Abl 抑制剂。Olverembatinib dimesylate 能广泛而有效地抑制突变型 Bcr-Abl。Olverembatinib dimesylate 对天然的 Bcr-Abl 和 Bcr-Abl^T315I 作用的 IC₅₀ 值分别为 0.34 nM 和 0.68 nM。Olverembatinib dimesylate 具有抗肿瘤作用。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Bcr-Abl

In Vitro: Olverembatinib dimesylate shows antiproliferative activity in stably transformed Ba/F3 cells whose growth was driven by native Bcr-Abl or Bcr-Abl mutants.
Olverembatinib dimesylate selectively and potently inhibits the proliferation of Bcr-Abl-positive leukemia cells.
Olverembatinib dimesylate inhibits Bcr-Abl signaling in K562 (1-20 nM; 4.0 hours) and Ba/F3 stable cell lines expressing native Bcr-Abl (0.1-100 nM; 4.0 hours) or Bcr-Abl^T315I(0.1-100 nM; 4.0 hours).

In Vivo: Olverembatinib dimesylate suppresses tumor growth in mice bearing allografted Ba/F3 cells expressing Bcr-Abl ^WT.
Olverembatinib dimesylate (1-20 mg/kg; i.g.; daily; for 10 days) significantly increases the median survival of the mice bearing allografted Ba/F3 cells expressing Bcr-Abl^T315I.
Olverembatinib dimesylate exhibits a good oral bioavailability (rat 48.7%) and C_max (rat 390.5 μg/L) following oral administration (rat; 25 mg/kg).
Olverembatinib dimesylate exhibits terminal elimination half-lives (rat 5.6 h) due to high plasma clearance (rat 1.7 L/h/kg) following intravenous administration (rat 5 mg/kg).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Anti-Alzheimer's Disease Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Dasatinib  |  Nocodazole  |  Imatinib  |  Ponatinib  |  Nilotinib  |  Bosutinib  |  Degrasyn  |  AT9283  |  Rebastinib  |  Asciminib  |  Bafetinib  |  KW-2449  |  Flumatinib  |  Olverembatinib  |  DPH  |  XL228  |  Cenisertib  |  AST 487  |  PD173955  |  GNF-7  |  GNF-5  |  SIAIS178  |  CZC-8004  |  GMB-475  |  GNF-2  |  Vodobatinib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。